Brief: Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash

Affimed NV

11/12/2017 10:01

Dec 11 (Reuters) - Affimed Nv  AFMD.O : 
    * Affimed presents data from Phase 1B combination study of 
AFM13 
with Pembrolizumab at Ash 
    * Affimed NV - completed dose-escalation shows combination 
of 
AFM13 and pembrolizumab is well-tolerated 
    * Affimed - 3-month ORR compares favorably to historical ORR 
of 
pembrolizumab alone in Phase 1B combination study of aFM13 
    * Affimed NV - one dose-limiting toxicity observed in Cohort 
3, 
which was repeated GRADE 2 infusion-related reaction 
    * Affimed NV - In Cohort 3, repeated Grade 2 
infusion-related 
reaction lead to discontinuation of AFM13 treatment 
 
Source text for Eikon:  ID:nGNXOJWCDa  
Further company coverage:  AFMD.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))